Table 3.
Baseline cardiac and neurologic measures of the patient groups
| Measures | Regular-Dose (n=24) | Dose-Reduction-Switch (n=28) | Switch (n=37) | Total (N=89) |
|---|---|---|---|---|
| Cardiac measures | ||||
| NYHA class | ||||
| 0 | 2 (10.5) | 3 (14.3) | 4 (12.9) | 9 (12.7) |
| I | 9 (47.4) | 9 (42.9) | 13 (41.9) | 31 (43.7) |
| II | 7 (36.8) | 6 (28.6) | 11 (35.4) | 24 (33.8) |
| III | 1 (5.3) | 3 (14.3) | 3 (9.7) | 7 (9.9) |
| IV | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| LV diastolic diameter, mm | 52.4±6.8a | 47.8±8.0 | 46.6±6.2 | 49.2±6.8 |
| LV systolic diameter, mm | 34.4±8.1 | 30.5±6.1 | 29.1±7.3 | 31.6±7.5 |
| LVSd, mm | 12.7±2.7 | 13.5±3.7 | 13.7±2.8 | 13.1±2.8 |
| LVH | 10 (55.6) | 10 (52.6) | 17 (70.8) | 37 (60.7) |
| Posterior wall diameter, mm | 12.2±2.4 | 12.3±3.4 | 12.8±2.8 | 12.3±2.7 |
| Ejection fraction, % | 60.1±8.9 | 60.3±5.1 | 61.8±6.9 | 60.8±7.2 |
| ECG abnormalities | 3 (15.8) | 5 (22.7) | 6 (24.0) | 14 (19.4) |
| Pacemaker | 3 (15.0) | 2 (9.1) | 2 (6.1) | 7 (9.3) |
| Neurologic measures | ||||
| CES-D score | 18.4±9.0 | 17.5±10.6 | 18.3±9.1 | 18.0±9.4 |
| GCPS 2 (maximum pain) | 4.6±2.9 | 5.3±2.3 | 3.8±3.8 | 4.6±3.0 |
| GCPS 5 (impairment) | 1.5±2.1 | 2.1±2.9 | 1.8±3.2 | 1.8±2.7 |
| NPSI sum score | 0.15±0.15 | 0.25±0.21 | 0.13±0.11 | 0.18±0.17 |
| Sural nerve | ||||
| SNAP, µV | 11.7±6.1 | 19.1±13.2 | 17.1±5.1 | 16.3±9.1 |
| NCV, m/s | 39.9±2.9 | 42.5±5.6 | 45.6±6.6 | 42.9±5.8 |
| CDT | −17.1±5.6 | −15.7±7.2 | −12.4±7.0 | −14.8±6.8 |
Values are given as mean±SD or n (%). Differences between groups have been tested via one-way ANOVA for continuous variables or Fisher’s exact test for categorical variables. Because of the multicenter approach, some parameters were not available for the entire study cohort. NYHA, New York Heart Association; LV, left ventricular; LVSd, left ventricular septum thickness in diastole; LVH, left ventricular hypertrophy (left ventricular septum thickness in diastole >12 mm); ECG, electrocardiogram; CES-D, Center for Epidemiologic Studies-Depression scale; GCPS, Graded Chronic Pain Scale; NPSI, Neuropathic Pain Symptom Inventory; SNAP, sensory nerve action potential; NCV, nerve conduction velocity; CDT, cold detection threshold.
P<0.05 for regular-dose versus switch group.